Info

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focusing on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The Company's principal programs are directed toward gastroenterology, virology and oncology. In the area of gastroenterology, its work is focused on methylnaltrexone, which is its principal product candidate. In the area of virology, Progenics is developing viral-entry inhibitors for human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), and Hepatitis C virus infection (HCV). In the area of prostate cancer, the Company is developing a human monoclonal antibody-drug conjugate, consisting of a selectively targeted cytotoxic antibody directed against prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells.(Source: 10-K)